Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The data comes from a report from Chicago-based consultancy firm Kaufman Hall, which releases a monthly analysis on the financial health of hospitals and health systems. Revenue growth is primarily driven by a rise of inpatient encounters.
According to a report published by the Commonwealth Fund, proposed federal budget cuts will devastate state economies, causing a ripple effect that leaves no industry unscathed.
CMS will cover TTVR for the treatment of symptomatic tricuspid regurgitation on a national level. The agency first proposed such a policy in December, taking time to consider public comments before finalizing its decision.
Motivity is receiving an injection of cash from Five Elms Capital, a software investment firm. The companies said the funds will be used to hire staff and improve products.
A study by researchers at Brown University and Duke University analyzed the employment records of 200 practices acquired by private equity firms and compared them with unacquired practices to develop some observations.